Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Evotec will leverage its iPSC know-how with stem cell-based disease modeling to discover novel drugs for retinal diseases.
Doctors in Paris discovered that when they treated an HIV-infected lung cancer patient with Opdivo, reservoirs of the virus shrunk.
Engineers at Duke University say they’ve created an artificial heart muscle that helps repair damage in patients who have suffered heart attacks.
AstraZeneca is allowing U.K. scientists access to an early-stage pipeline med in the hope it can help patients with head and neck cancer.
Scientists have identified viral changes and antibody features that could provide a possible template for HIV vaccine design.
Certain microRNAs in the saliva of concussion patients could help gauge the severity of concussions and predict the length of concussion symptoms.
The enzyme PTK6 could be targeted to quell the growth of estrogen receptor-positive breast cancer, a common form of the disease.
Researchers in the U.K. tested AstraZeneca’s PARP inhibitor Lynparza and found it can penetrate the blood-brain barrier and invade glioblastoma tumors.
Broad Institute scientists have created an RNA-editing method that makes reversible changes to DNA possible.
MIT scientists have devised a gene circuit that could identify cancer cells more accurately and stimulate the immune system more effectively.